Managing CNS diseases at the point of diagnosis in ALK + NSCLC

Speciality: Oncology

Description:

Welcome to today’s insightful discussion on managing CNS diseases in ALK-positive NSCLC, introduced by Dr. Sushant Mittal, with an esteemed panel featuring Dr. Randeep Singh, a leading medical oncologist, and Dr. Tarachand Gupta, known for his clinical expertise in lung cancer. This panel aims to address the critical nuances in identifying and treating central nervous system (CNS) involvement right at the point of diagnosis in ALK-positive non-small cell lung cancer (NSCLC). With the rising incidence of CNS metastases in this subset of lung cancer patients, early detection and appropriate management are essential to improve outcomes.

ALK-positive NSCLC has a high tendency for CNS involvement, often present even at diagnosis. The discussion highlights the importance of baseline brain MRI, molecular profiling, and using CNS-penetrant ALK inhibitors such as alectinib, lorlatinib, and brigatinib as first-line treatments. These next-generation inhibitors demonstrate superior intracranial control, CNS progression-free survival, and efficacy across the blood-brain barrier, compared to earlier agents like crizotinib. The panel also emphasized the need for early CNS screening, liquid biopsies, and precision oncology in customizing treatment strategies. Avoiding prophylactic cranial irradiation when possible and focusing on real-world data to guide practice were also key takeaways.

Thank you for joining us in this important discussion on CNS disease management in ALK+ NSCLC. Special thanks to Dr. Sushant Mittal for leading the session, and to Dr. Randeep Singh and Dr. Tarachand Gupta for their valuable insights. Stay tuned for more expert-driven sessions that bring clarity and clinical relevance to challenging oncology topics. Keep watching for more such updates and in-depth conversations designed to empower clinicians and improve patient care.

See More Webinars @ Hidoc Webinars